Advanced search
Publication Cover
Therapeutic Delivery Volume 3, 2012 - Issue 4
Submit an article Journal homepage
226
Views
0
CrossRef citations to date
0
Altmetric
Review

Liposomes for Cardiovascular Targeting

Tatyana S Levchenkoa The Center for Pharmaceutical Biotechnology & Nanomedicine Department of Pharmaceutical Sciences Northeastern UniversityMugar BuildingRoom 312360 Huntington AvenueBostonMA02115USA
,
William C Hartnera The Center for Pharmaceutical Biotechnology & Nanomedicine Department of Pharmaceutical Sciences Northeastern UniversityMugar BuildingRoom 312360 Huntington AvenueBostonMA02115USA
&
Vladimir P Torchilinb The Center for Pharmaceutical Biotechnology & Nanomedicine Department of Pharmaceutical Sciences Northeastern UniversityMugar BuildingRoom 312360 Huntington [email protected]
Pages 501-514 | Published online: 29 Mar 2012

References

  • Chazov EI , AlexeevAV, AntonovASet al. Endothelial cell culture on fibrillar collagen: model to study platelet adhesion and liposome targeting to intercellular collagen matrix. Proc. Natl Acad. Sci. USA 78(9), 5603–5607 (1981).
  • Klibanov AL , MuzykantovVR, IvanovNN, TorchilinVP. Evaluation of quantitative parameters of the interaction of antibody-bearing liposomes with target antigens. Anal. Biochem.150(2), 251–257 (1985).
  • Jennings RB , SchaperJ, HillML, SteenbergenC Jr, Reimer KA. Effect of reperfusion late in the phase of reversible ischemic injury. Changes in cell volume, electrolytes, metabolites, and ultrastructure. Circ. Res.56(2), 262–278 (1985).
  • Bloemen PG , HenricksPA, Van Bloois L et al. Adhesion molecules: a new target for immunoliposome-mediated drug delivery. FEBS Lett.357(2), 140–144 (1995).
  • Das M , DasDK. Lipid raft in cardiac health and disease. Curr. Cardiol. Rev.5(2), 105–111 (2009).
  • Gunawan RC , AugusteD. Immunoliposomes that target endothelium in vitro are dependent on lipid raft formation. Mol. Pharm.7(5), 1569–1575 (2010).
  • Bendas G , KrauseA, SchmidtR, VogelJ, RotheU. Selectins as new targets for immunoliposome-mediated drug delivery. A potential way of anti-inflammatory therapy. Pharm. Acta Helv.73(1), 19–26 (1998).
  • Bendas G , KrauseA, BakowskyU, VogelJ, RotheU. Targetability of novel immunoliposomes prepared by a new antibody conjugation technique. Intl J. Pharm.181(1), 79–93 (1999).
  • Kessner S , KrauseA, RotheU, BendasG. Investigation of the cellular uptake of E-selectin-targeted immunoliposomes by activated human endothelial cells. Biochim. Biophys. Acta1514(2), 177–190 (2001).
  • Bendas G , RotheU, ScherphofGL, KampsJA. The influence of repeated injections on pharmacokinetics and biodistribution of different types of sterically stabilized immunoliposomes. Biochim. Biophys. Acta1609(1), 63–70 (2003).
  • Khaw BA , NarulaJ, KankeMet al. Application of monoclonal antibodies in cardiovascular diseases: atherosclerosis and pulmonary emboli imaging. J. Nucl. Biol. Med. 36(Suppl. 2), 35–40 (1992).
  • Knight LC . Antifibrin antibody for detection of deep vein thrombosis. In: Monoclonal Antibodies in Cardiovascular Diseases. Khaw BA, Narula J, Strauss HW (Eds). Lea and Febiger, Malvern, PA, USA. 171–186 (1994).
  • Tekabe Y , EinsteinAJ, JohnsonLL, KhawBA. Targeting very small model lesions pretargeted with bispecific antibody with 99mTc-labeled high-specific radioactivity polymers. Nucl. Med. Commun.31(4), 320–327 (2010).
  • Narula J , PetrovA, PakKY, DitlowC, ChenF, KhawBA. Noninvasive detection of atherosclerotic lesions by 99mTc-based immunoscintigraphic targeting of proliferating smooth muscle cells. Chest111(6), 1684–1690 (1997).
  • Carrio I , PieriPL, NarulaJet al. Noninvasive localization of human atherosclerotic lesions with indium 111-labeled monoclonal Z2D3 antibody specific for proliferating smooth muscle cells. J. Nucl. Cardiol. 5(6), 551–557 (1998).
  • Erdogan S , OzerAY, BilgiliH. In vivo behaviour of vesicular urokinase. Intl J. Pharm.295(1–2), 1–6 (2005).
  • Erdogan S , OzerAY, VolkanB, CanerB, BilgiliH. Thrombus localization by using streptokinase containing vesicular systems. Drug Deliv.13(4), 303–309 (2006).
  • Alkan-Onyuksel H , DemosSM, LanzaGMet al. Development of inherently echogenic liposomes as an ultrasonic contrast agent. J. Pharm. Sci. 85(5), 486–490 (1996).
  • Hamilton A , HuangSL, WarnickDet al. Left ventricular thrombus enhancement after intravenous injection of echogenic immunoliposomes: studies in a new experimental model. Circulation 105(23), 2772–2778 (2002).
  • Demos SM , OnyukselH, GilbertJet al. In vitro targeting of antibody-conjugated echogenic liposomes for site-specific ultrasonic image enhancement. J. Pharm. Sci.86(2), 167–171 (1997).
  • Demos SM , DagarS, KlegermanM, NagarajA, McphersonDD, OnyukselH. In vitro targeting of acoustically reflective immunoliposomes to fibrin under various flow conditions. J. Drug Target.5(6), 507–518 (1998).
  • Demos SM , Alkan-OnyukselH, KaneBJet al. In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement. J. Am. Coll. Cardiol.33(3), 867–875 (1999).
  • Danila D , ParthaR, ElrodDB, LackeyM, CasscellsSW, ConyersJL. Antibody-labeled liposomes for CT imaging of atherosclerotic plaques: in vitro investigation of an anti-ICAM antibody-labeled liposome containing iohexol for molecular imaging of atherosclerotic plaques via computed tomography. Tex. Heart Inst. J.36(5), 393–403 (2009).
  • Mulder WJ , StrijkersGJ, GriffioenAWet al. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug. Chem. 15(4), 799–806 (2004).
  • Almer G , WernigK, Saba-LepekMet al. Adiponectin-coated nanoparticles for enhanced imaging of atherosclerotic plaques. Intl J. Nanomed. 6, 1279–1290 (2011).
  • Maiseyeu A , MihaiG, KampfrathTet al. Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis. J. Lipid Res. 50(11), 2157–2163 (2009).
  • Lobatto ME , FayadZA, SilveraSet al. Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol. Pharm. 7(6), 2020–2029 (2010).
  • Kim H , MoodyMR, LaingSTet al. In vivo volumetric intravascular ultrasound visualization of early/inflammatory arterial atheroma using targeted echogenic immunoliposomes. Invest. Radiol.45(10), 685–691 (2010).
  • Kim TD , KambayashiJ, SakonM, TsujinakaT, OhshiroT, MoriT. Metabolism of liposome-encapsulated heparin. Thromb. Res.56(3), 369–376 (1989).
  • Passirani C , BarrattG, DevissaguetJP, LabarreD. Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). Pharm. Res.15(7), 1046–1050 (1998).
  • Passirani C , FerrariniL, BarrattG, DevissaguetJP, LabarreD. Preparation and characterization of nanoparticles bearing heparin or dextran covalently-linked to poly(methyl methacrylate). J. Biomater. Sci. Polym. Ed.10(1), 47–62 (1999).
  • Jiao YY , UbrichN, HoffartVet al. Preparation and characterization of heparin-loaded polymeric microparticles. Drug Dev. Ind. Pharm. 28(8), 1033–1041 (2002).
  • Luo X , QiuD, HeB, WangL, LuoJ. Biodegradable heparin-loaded microspheres: carrier molecular composition and microsphere structure. Macromol. Biosci.6(5), 373–381 (2006).
  • Bai S , ThomasC, AhsanF. Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin. J. Pharm. Sci.96(8), 2090–2106 (2007).
  • Heeremans JL , PrevostR, BekkersMEet al. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA. Thromb. Haemost. 73(3), 488–494 (1995).
  • Uesugi Y , KawataH, JoJ, SaitoY, TabataY. An ultrasound-responsive nano delivery system of tissue-type plasminogen activator for thrombolytic therapy. J. Control. Release147(2), 269–277 (2010).
  • Hua X , LiuP, GaoYHet al. Construction of thrombus-targeted microbubbles carrying tissue plasminogen activator and their in vitro thrombolysis efficacy: a primary research. J. Thromb. Thrombolysis 30(1), 29–35 (2010).
  • Villanueva FS , LuE, BowrySet al. Myocardial ischemic memory imaging with molecular echocardiography. Circulation 115(3), 345–352 (2007).
  • Klibanov AL . Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Invest. Radiol.41(3), 354–362 (2006).
  • Lindner JR . Contrast ultrasound molecular imaging of inflammation in cardiovascular disease. Cardiovasc. Res.84(2), 182–189 (2009).
  • Smith AH , FujiiH, KuliszewskiMA, Leong-PoiH. Contrast ultrasound and targeted microbubbles: diagnostic and therapeutic applications for angiogenesis. J. Cardiovasc. Transl. Res.4(4), 404–415 (2011).
  • Tiukinhoy-Laing SD , HuangS, KlegermanM, HollandCK, McphersonDD. Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes. Thromb. Res.119(6), 777–784 (2007).
  • Tiukinhoy-Laing SD , BuchananK, ParikhDet al. Fibrin targeting of tissue plasminogen activator-loaded echogenic liposomes. J. Drug Target. 15(2), 109–114 (2007).
  • Laing ST , MoodyM, SmulevitzBet al. Ultrasound-enhanced thrombolytic effect of tissue plasminogen activator-loaded echogenic liposomes in an in vivo rabbit aorta thrombus model-brief report. Arterioscler. Thromb. Vac. Biol. 31(6), 1357–1359 (2011).
  • Perkins WR , VaughanDE, PlavinSRet al. Streptokinase entrapment in interdigitation-fusion liposomes improves thrombolysis in an experimental rabbit model. Thromb. Haemost. 77(6), 1174–1178 (1997).
  • Leach JK , O‘rearEA, PattersonE, MiaoY, JohnsonAE. Accelerated thrombolysis in a rabbit model of carotid artery thrombosis with liposome-encapsulated and microencapsulated streptokinase. Thromb. Haemost.90(1), 64–70 (2003).
  • Vaidya B , NayakMK, DashD, AgrawalGP, VyasSP. Development and characterization of site specific target sensitive liposomes for the delivery of thrombolytic agents. Intl J. Pharm.403(1–2), 254–261 (2011).
  • Lu CP , YangH, WangJ, DongXL. Thrombolysis of rabbit‘s pulmonary embolism with thrombus-targeted urokinase immune liposome. Zhonghua Xin Xue Guan Bing Za Zhi37(11), 1035–1038 (2009).
  • Meyenburg S , LilieH, PanznerS, RudolphR. Fibrin encapsulated liposomes as protein delivery system. Studies on the in vitro release behavior. J. Control. Release69(1), 159–168 (2000).
  • Gupta AS , HuangG, LestiniBJ, SagnellaS, Kottke-MarchantK, MarchantRE. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. Thromb. Haemost.93(1), 106–114 (2005).
  • Huang G , ZhouZ, SrinivasanRet al. Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets. Biomaterials 29(11), 1676–1685 (2008).
  • Freude B , MastersTN, RobicsekFet al. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J. Mol. Cell. Cardiol. 32(2), 197–208 (2000).
  • Scarabelli T , StephanouA, RaymentNet al. Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. Circulation 104(3), 253–256 (2001).
  • Gottlieb RA , BurlesonKO, KlonerRA, BabiorBM, EnglerRL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J. Clin. Invest.94(4), 1621–1628 (1994).
  • Kajstura J , ChengW, ReissKet al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab. Invest. 74(1), 86–107 (1996).
  • Nakagawa T , ShimizuS, WatanabeTet al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434(7033), 652–658 (2005).
  • Jennings RB , SommersHM, SmythGA, FlackHA, LinnH. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch. Pathol.70, 68–78 (1960).
  • Khaw BA , BellerGA, HaberE, SmithTW. Localization of cardiac myosin-specific antibody in myocardial infarction. J. Clin. Invest.58(2), 439–446 (1976).
  • Khaw BA , FallonJT, BellerGA, HaberE. Specificity of localization of myosin-specific antibody fragments in experimental myocardial infarction. Histologic, histochemical, autoradiographic and scintigraphic studies. Circulation60(7), 1527–1531 (1979).
  • Reimer KA , JenningsRB, TatumAH. Pathobiology of acute myocardial ischemia: metabolic, functional and ultrastructural studies. Am. J. Cardiol.52(2), 72A–81A (1983).
  • Braunwald E , KlonerRA. Myocardial reperfusion: a double-edged sword? J. Clin. Invest.76(5), 1713–1719 (1985).
  • Khaw BA , TorchilinVP, VuralI, NarulaJ. Plug and seal: prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes. Nat. Med.1(11), 1195–1198 (1995).
  • Khaw BA , VuralI, NarulaJ, HaiderN, TorchilinVP. Preservation of cardiocyte viability by immunoliposome-cell membrane sealing at 1, 2, 3, 4 and 5 days of hypoxia. Presented at: 23rd International Symposium of Controlled Release of Bioactive Materials. Kyoto, Japan, 11–12 July 1996.
  • Caride VJ , ZaretBL. Liposome accumulation in regions of experimental myocardial infarction. Science198(4318), 735–738 (1977).
  • Kayawake S , KakoKJ. Association of liposomes with the isolated perfused rabbit heart. Basic Res. Cardiol.77(6), 668–681 (1982).
  • Palmer TN , CaldecourtMA, KingabyRO. Liposomal drug delivery in chronic ischaemia. Biochem. Soc. Trans.12(2), 344–345 (1984).
  • Palmer TN , CarideVJ, CaldecourtMA, TwicklerJ, AbdullahV. The mechanism of liposome accumulation in infarction. Biochim. Biophys. Acta797(3), 363–368 (1984).
  • Torchilin VP , KhawBA, SmirnovVN, HaberE. Preservation of antimyosin antibody activity after covalent coupling to liposomes. Biochem. Biophys. Res. Commun.89(4), 1114–1119 (1979).
  • Klibanov AL , MaruyamaK, TorchilinVP, HuangL. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett.268(1), 235–237 (1990).
  • Torchilin VP . Targeting of thrombolytic agents: current state of knowledge and perspectives. Annu. NY Acad. Sci.667, 404–416 (1992).
  • Torchilin VP , NarulaJ, HalpernE, KhawBA. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. Biochim. Biophys. Acta1279(1), 75–83 (1996).
  • Khaw BA , KhudairiT. Dose-response to cytoskeletal-antigen specific immunoliposome therapy for preservation of myocardial viability and function in langendorff instrumented rat hearts. J. Liposome Res.17(2), 63–77 (2007).
  • Khaw BA , DasilvaJ, HartnerWC. Cytoskeletal-antigen specific immunoliposome-targeted in vivo preservation of myocardial viability. J. Control. Release120(1–2), 35–40 (2007).
  • Scott RC , WangB, NallamothuRet al. Targeted delivery of antibody conjugated liposomal drug carriers to rat myocardial infarction. Biotechnol. Bioeng. 96(4), 795–802 (2007).
  • Wang B , ScottRC, PattilloCB, PrabhakarpandianB, SundaramS, KianiMF. Modeling oxygenation and selective delivery of drug carriers post-myocardial infarction. Adv. Exp. Med. Biol.614, 333–343 (2008).
  • Scott RC , RosanoJM, IvanovZet al. Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J. 23(10), 3361–3367 (2009).
  • Nguyen PD , O‘rearEA, JohnsonAE, PattersonE, WhitsettTL, BhaktaR. Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase. Circ. Res.66(3), 875–878 (1990).
  • Leach JK , PattersonE, O‘rearEA. Improving thrombolysis with encapsulated plasminogen activators and clinical relevance to myocardial infarction and stroke. Clin. Hemorheol. Microcirc.30(3–4), 225–228 (2004).
  • Tang CS , SuJY, LiZPet al. Possibility of targeting treatment for ischemic heart disease with liposome (I). Sci. China B. 36(5), 590–598 (1993).
  • Tang CS , SuJY, LiZPet al. Possibility of targeting treatment for ischemic heart disease with liposome (II). Sci. China B. 36(7), 809–816 (1993).
  • Suzuki K , SawaY, IchikawaH, KanedaY, MatsudaH. Myocardial protection with endogenous overexpression of manganese superoxide dismutase. Annu. Thorac. Surg.68(4), 1266–1271 (1999).
  • Jadot G , MichelsonAM. Comparative anti-inflammatory activity of different superoxide dismutases and liposomal SOD in ischemia. Free Radic. Res. Commun.3(6), 389–394 (1987).
  • Phelan AM , LangeDG. Ischemia/reperfusion-induced changes in membrane fluidity characteristics of brain capillary endothelial cells and its prevention by liposomal-incorporated superoxide dismutase. Biochim. Biophys. Acta1067(1), 97–102 (1991).
  • Bkaily G , SperelakisN, ElishalomY, BarenholzY. Effect of Na+- or Ca2+-filled liposomes on electrical activity of cultured heart cells. Am. J. Physiol.245(5 Suppl. 1), H756–H761 (1983).
  • Han YY , HuangL, JacksonEK, DubeyRK, GillepsieDG, CarcilloJA. Liposomal ATP or NAD+ protects human endothelial cells from energy failure in a cell culture model of sepsis. Res. Commun. Mol. Pathol. Pharmacol.110(1–2), 107–116 (2001).
  • Xu GX , XieXH, LiuFYet al. Adenosine triphosphate liposomes: encapsulation and distribution studies. Pharm. Res. 7(5), 553–557 (1990).
  • Verma DD , LevchenkoTS, BernsteinEA, TorchilinVP. ATP-loaded liposomes effectively protect mechanical functions of the myocardium from global ischemia in an isolated rat heart model. J. Control. Release108(2–3), 460–471 (2005).
  • Verma DD , HartnerWC, LevchenkoTS, BernsteinEA, TorchilinVP. ATP-loaded liposomes effectively protect the myocardium in rabbits with an acute experimental myocardial infarction. Pharm. Res.22(12), 2115–2120 (2005).
  • Verma DD , LevchenkoTS, BernsteinEA, MongaytD, TorchilinVP. ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model. J. Drug Target.14(5), 273–280 (2006).
  • Khaw BA , NarulaJ, VuralI, TorchilinVP. Cytoskeleton-specific immunoliposomes: sealing of hypoxic cells and intracellular delivery of DNA. Intl J. Pharm.162(1), 71–76 (1998).
  • Khaw BA , DasilvaJ, VuralI, NarulaJ, TorchilinVP. Intracytoplasmic gene delivery for in vitro transfection with cytoskeleton-specific immunoliposomes. J. Control. Release75(1–2), 199–210 (2001).
  • Ko YT , HartnerWC, KaleA, TorchilinVP. Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide. Gene Ther.16(1), 52–59 (2009).
  • Tanabe K , SerruysPW, DegertekinMet al. Fate of side branches after coronary arterial sirolimus-eluting stent implantation. Am. J. Cardiol. 90(9), 937–941 (2002).
  • Grube E , SilberS, HauptmannKEet al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107(1), 38–42 (2003).
  • Liistro F , StankovicG, Di Mario C et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation105(16), 1883–1886 (2002).
  • Antimisiaris SG , KoromilaG, MichanetzisG, MissirlisYF. Liposome coated stents: a method to deliver drugs to the site of action and improve stent blood-compatibility. J. Liposome Res.16(3), 303–309 (2006).
  • Kallinteri P , AntimisiarisSG, KarnabatidisD, KalogeropoulouC, TsotaI, SiablisD. Dexamethasone incorporating liposomes: an in vitro study of their applicability as a slow releasing delivery system of dexamethasone from covered metallic stents. Biomaterials23(24), 4819–4826 (2002).
  • Koromila G , MichanetzisGP, MissirlisYF, AntimisiarisSG. Heparin incorporating liposomes as a delivery system of heparin from PET-covered metallic stents: effect on haemocompatibility. Biomaterials27(12), 2525–2533 (2006).
  • Brito LA , ChandrasekharS, LittleSR, AmijiMM. In vitro and in vivo studies of local arterial gene delivery and transfection using lipopolyplexes-embedded stents. J. Biomed. Mater. Res. A93(1), 325–336 (2010).
  • Sharif F , HynesSO, MccullaghKJet al. Gene-eluting stents: non-viral, liposome-based gene delivery of eNOS to the blood vessel wall in vivo results in enhanced endothelialization but does not reduce restenosis in a hypercholesterolemic model. Gene Ther. 19(3), 321–328 (2011).
  • Whelan RS , KaplinskiyV, KitsisRN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu. Rev. Physiol.17(72), 19–44 (2010).
  • Lammers T , AimeS, HenninkWE, StormG, KiesslingF. Theranostic nanomedicines. Acc. Chem. Res.44(10), 1029–1038 (2011).
  • Mccarthy JR . Multifunctional agents for concurrent imaging and therapy in cardiovascular disease. Adv. Drug Deliv. Rev.62(11), 1023–1030 (2010).
  • Voinea M , ManduteanuI, DragomirE, CapraruM, SimionescuM. Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells – a potential tool for specific drug delivery. Pharm. Res.22(11), 1906–1917 (2005).
  • Saito A , ShimizuH, DoiYet al. Immunoliposomal drug-delivery system targeting lectin-like oxidized low-density lipoprotein receptor-1 for carotid plaque lesions in rats. J. Neurosurg. 115(4), 720–727 (2011).
  • Herbst SM , KlegermanME, KimHet al. Delivery of stem cells to porcine arterial wall with echogenic liposomes conjugated to antibodies against CD34 and intercellular adhesion molecule-1. Mol. Pharm. 7(1), 3–11 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.